Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06215118 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

StatusActive, Not Recruiting
PhasePhase 1
SponsorPfizer
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 7 months later Apr 10, 2027 → Nov 16, 2027
See other at-risk trials from Pfizer

Record History

  1. Primary completion pushed from Apr 10, 2027 to Nov 16, 2027 Enrollment closed, study ongoing · Final enrollment: 100 participants (planned 87) · Completion pushed from Mar 9, 2028 to Oct 15, 2028 · 3 more Show all 7 changesShow less
    • Enrollment closed, study ongoing
    • Final enrollment: 100 participants (planned 87)
    • Completion pushed from Mar 9, 2028 to Oct 15, 2028
    • Eligibility criteria expanded, about 18 words
    • Secondary endpoints: details revised at 3 of 14 entries
    • Site details revised at 43 of 43 sites
  2. Site details revised at 4 of 43 sitesv33
  3. Site details revised at 7 of 43 sitesv32
  4. Trial sites expanded: 21 → 43 locationsv31
  5. Trial sites reduced: 43 → 21 locationsv30
Show 28 earlier versionsHide 28 earlier versions
  1. Re-verified, no change to tracked fieldsv29
  2. Study sites: 38 to 43v28
  3. Re-verified, no change to tracked fieldsv27
  4. Study sites: 37 to 38v26
  5. Re-verified, no change to tracked fieldsv25
  6. Study sites: 35 to 37v24
  7. Study Status, Contacts/Locationsv23
  8. Study Status, Contacts/Locationsv22
  9. Re-verified, no change to tracked fieldsv21
  10. Study sites: 34 to 35v20
  11. Re-verified, no change to tracked fieldsv19
  12. Study sites: 31 to 34v18
  13. Study sites: 30 to 31v17
  14. Site details revised at 6 of 30 sitesv16
  15. Study sites: 25 to 30 Primary completion date: Mar 30, 2027 to Apr 10, 2027 · Completion date: Feb 27, 2028 to Mar 9, 2028v15 Show all 3 changesShow less
    • Primary completion date: Mar 30, 2027 to Apr 10, 2027
    • Completion date: Feb 27, 2028 to Mar 9, 2028
  16. Primary completion date: Jun 8, 2027 to Mar 30, 2027 Completion date: May 7, 2028 to Feb 27, 2028v14 Show all 2 changesShow less
    • Completion date: May 7, 2028 to Feb 27, 2028
  17. Study sites: 23 to 25 Primary completion date: Jul 2, 2027 to Jun 8, 2027 · Completion date: May 31, 2028 to May 7, 2028v13 Show all 3 changesShow less
    • Primary completion date: Jul 2, 2027 to Jun 8, 2027
    • Completion date: May 31, 2028 to May 7, 2028
  18. Study sites: 22 to 23 Primary completion date: Jun 3, 2027 to Jul 2, 2027 · Completion date: May 2, 2028 to May 31, 2028v12 Show all 3 changesShow less
    • Primary completion date: Jun 3, 2027 to Jul 2, 2027
    • Completion date: May 2, 2028 to May 31, 2028
  19. Site details revised at 9 of 22 sitesv11
  20. Enrollment target: 100 to 87 Study sites: 17 to 22 · Primary completion date: Aug 28, 2027 to Jun 3, 2027 · Completion date: Jul 27, 2028 to May 2, 2028v10 Show all 4 changesShow less
    • Study sites: 17 to 22
    • Primary completion date: Aug 28, 2027 to Jun 3, 2027
    • Completion date: Jul 27, 2028 to May 2, 2028
  21. Study sites: 13 to 17 Primary completion date: Aug 6, 2027 to Aug 28, 2027 · Completion date: Jul 5, 2028 to Jul 27, 2028v9 Show all 3 changesShow less
    • Primary completion date: Aug 6, 2027 to Aug 28, 2027
    • Completion date: Jul 5, 2028 to Jul 27, 2028
  22. Study sites: 10 to 13 Primary completion date: Apr 10, 2027 to Aug 6, 2027 · Completion date: Mar 9, 2028 to Jul 5, 2028v8 Show all 3 changesShow less
    • Primary completion date: Apr 10, 2027 to Aug 6, 2027
    • Completion date: Mar 9, 2028 to Jul 5, 2028
  23. Study sites: 8 to 10v7
  24. 2 versions Re-verified since Apr 11, 2024, no change to tracked fieldsv5-v6
  25. Study sites: 1 to 8v4
  26. Re-verified, no change to tracked fieldsv3
  27. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Aug 13, 2026 to Apr 10, 2027 · Study sites: 0 to 1 · Completion date: Jun 17, 2028 to Mar 9, 2028 · 1 morev2 Show all 5 changesShow less
    • Primary completion date: Aug 13, 2026 to Apr 10, 2027
    • Study sites: 0 to 1
    • Completion date: Jun 17, 2028 to Mar 9, 2028
    • Start date changed from estimate of Feb 3, 2024 to Feb 20, 2024
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Pfizer
433 trials monitored
See 31 trials at risk
Multiple Myeloma
1,231 trials monitored
See 77 trials at risk
The main purpose of the study is to understand how safe and tolerable is elranatamab when given along with iberdomide. There are 2 parts to this study. Part 1 will look at how safe and tolerable is elranatamab when given with iberdomide. Part 2 will look at the correct amount of this combination that can be given to patients with relapsed or refractory multiple myeloma. Myeloma is a type of cancer that begins in plasma cells (white blood cells that produce antibodies). Refractory means a disease or condition that does not respond to treatment. Relapsed means the return of a disease after a period of improvement. All study medicines are given in cycles that last 28 days. Everyone taking part in this study will receive elranatamab as a shot under the skin. Iberdomide will be taken by mouth once a day for 21 days over a 28-day cycle. Participants will receive study medicine until: * their disease progresses or, * they experience unacceptable side effects or, * they choose to no longer take part in the study. The study will look at the experiences of people receiving the study medicines. This will help see if the study medicines are safe and can be used for multiple myeloma treatment.
Trial Details
NCT Number NCT06215118
Lead Sponsor Pfizer
Collaborators: Bristol-Myers Squibb
Conditions Multiple Myeloma
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov